| DESCRIPTION | - ATANUR et al., Genome Res, (20100000), vol. 20, pages 791 - 803 | - |
| DESCRIPTION | - BAKRIS et al., Hypertension, (20100000), vol. 56, pages 824 - 830 | - |
| DESCRIPTION | - DENOLLE et al., J Hum Hypertens, (20160000), vol. 30, no. 11, pages 657 - 663 | - |
| DESCRIPTION | - GAVRAS et al., Circ. Res., (19750000), vol. 36, pages 300 - 309 | - |
| DESCRIPTION | - GODDARD et al., J.Am.Soc.Nephrol., (20040000), vol. 15, pages 2601 - 2610 | - |
| DESCRIPTION | - IGLARZ et al., J. Pharmacol. Exp. Ther., (20080000), vol. 327, no. 3, pages 736 - 745 | - |
| DESCRIPTION | - JANIAK et al., Eur. J. Pharmacol., (20060000), vol. 534, pages 271 - 279 | - |
| DESCRIPTION | - LAFFIN et al., Seminars in Nephrology, (20150000), vol. 35, pages 168 - 175 | - |
| DESCRIPTION | - MANCIA et al., J. Hypertens, (20130000), vol. 31, page 1281 1357 | - |
| DESCRIPTION | - MANCIA et al., J. Hypertens., (20130000), vol. 31, pages 1281 - 1357 | - |
| DESCRIPTION | - MANN et al., J Am Soc Nephrol, (20100000), vol. 21, no. 3, pages 527 - 535 | - |
| DESCRIPTION | - MCCORMACK et al., Br J Cardiol, (20130000), vol. 20, pages S1 - S16 | - |
| DESCRIPTION | - RAPP, Hypertension, (19820000), vol. 4, pages 753 - 763 | - |
| DESCRIPTION | - SEN et al., Life Sci., (20120000), vol. 91, pages 13 - 14 | - |
| DESCRIPTION | - VERCAUTEREN et al., JPET, (20170000), vol. 361, pages 322 - 333 | - |
| DESCRIPTION | - WEBER et al., "Clinical Practice Guidelines for the Management of Hypertension in the Community. A Statement by the American Society of Hypertension and the International Society of Hypertension", J Clin Hypertens, (20140000), vol. 16, no. 1, pages 14 - 26 | - |
| EXAMINATION | - WEBER M A ET AL, "A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial", THE LANCET, ELSEVIER, AMSTERDAM, NL, vol. 374, no. 9699, doi:10.1016/S0140-6736(09)61500-2, ISSN 0140-6736, (20091024), pages 1423 - 1431, (20091024), XP026721787 | |
| OPPOSITION | - Actelion Pharmaceuticals Ltd, "Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia", Intrado GlobalNewsWire, (20170522), pages 1 - 10, Intrado GlobalNewsWire, URL: https://www.globenewswire.com/news-release/2017/05/22/994421/0/en/Actelion-provides-an-update-on-the-progress-towards-launching-Idorsia-Key-results-for-pipeline-assets-to-be-developed-by-Idorsia.html, (20210908), XP055839178 | - |
| OPPOSITION | - Actelion’s cardiovascular pipeline investor webcast, 7 November 2016 | - |
| OPPOSITION | - Allen Jr L V, Luner, P E, "Magnesium Stearate", Allen Jr L V, Luner, P E, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090203), pages 404 - 407, ISBN 978-0-85369-792-3, XP055956908 | - |
| OPPOSITION | - Anonymous, "KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease", Official Journal of the International Society of Nephrology, (20120101), Official Journal of the International Society of Nephrology, URL: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf, XP093282268 | - |
| OPPOSITION | - Bakris George, Et Al., "Divergent Results Using Clinic and Ambulatory Blood Pressures Report of a Darusentan-Resistant Hypertension Trial", Hypertension, (20101101), pages 824 - 830, Hypertension, URL: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.110.156976, (20210908), XP055839026 | - |
| OPPOSITION | - F. Trenz et al., ET-15 Conference, abstract, 15 October 2017 | - |
| OPPOSITION | - F. Trenz et al., ET-15 Conference, presentation, 15 October 2017 | - |
| OPPOSITION | - Guest R T, "Croscarmellose Sodium", Guest R T, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090206), pages 206 - 208, ISBN 978-0-85369-792-3, XP093234018 | - |
| OPPOSITION | - "Lactose, Monohydrate and Microcrystalline Cellulose", Raymond C Rowe, Handbook of Pharmaceutical Excipients - Sixth Edition, Pharmaceutical Press , (20090101), pages 371 - 373, ISBN 978 0 85369 792 3, XP009561922 | - |
| OPPOSITION | - "Lactose, Monohydrate and Povidone", Raymond C Rowe, Handbook of Pharmaceutical Excipients - Sixth Edition, Pharmaceutical Press , (20090101), pages 373 - 374, ISBN 978 0 85369 792 3, XP009561924 | - |
| OPPOSITION | - MA Kabir, JP Reo, "Hydroxypropyl Cellulose", MA Kabir, JP Reo, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090223), pages 317 - 322, ISBN 978-0-85369-792-3, XP093163295 | - |
| OPPOSITION | - Rowe Raymond C, Et Al, "Cellulose, Microcrystalline", Rowe Raymond C, Et Al, Raymond C Rowe; Paul J Sheskey; Marian E Quinn (eds.), Handbook of Pharmaceutical Excipients, UK , Pharmaceutical Press , (20090101), pages 129 - 133, ISBN 978-0-85369-792-3, XP055796468 | - |
| OPPOSITION | - Sakr Ahmed Adel, Et Al, "Chapter 30 oral solid dosage forms", Remington Essentials of Pharmaceutics, Pharmaceutical Press , (20120101), pages 581 - 610, XP055795831 | - |
| OPPOSITION | - Supplementary appendix to M.P. Schlaich et al., The Lancet, 2022, 400(10367), 1-11 | - |
| OPPOSITION | - Verweij Pierre, Et Al., "Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension", Hypertension, (20200401), pages 956 - 965, Hypertension, URL: https://www.ahajournals.org/doi/10.1161/HYPERTENSIONAHA.119.14504, (20210908), XP055839036 | - |
| OPPOSITION | - William J. Reilly, "Chapter 36 Pharmaceutical Excipients", Remington, Essentials of Pharmaceutics, GB, Pharmaceutical Press , (20130101), pages 683 - 704, ISBN 978-0-85711-105-0, XP093163239 | - |
| OPPOSITION | - P. N. Sidharta, A. Treiber, J. Dingemanse, "Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan", CLINICAL PHARMACOKINETICS., ADIS INTERNATIONAL LTD., AUCKLAND, NZ, NZ , (20150501), vol. 54, no. 5, doi:10.1007/s40262-015-0255-5, ISSN 0312-5963, pages 457 - 471, XP055614382 | |
| OPPOSITION | - Marc Iglarz, Alexandre Bossu, Daniel Wanner, Céline Bortolamiol, Markus Rey, Patrick Hess, Martine Clozel, "Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension", Life Science, PERGAMON PRESS, OXFORD, GB, GB , (20141101), vol. 118, no. 2, doi:10.1016/j.lfs.2014.02.018, ISSN 0024-3205, pages 333 - 339, XP055704917 | |
| OPPOSITION | - Maguire Janet J., Davenport Anthony P., "Endothelin Receptors and Their Antagonists", Seminars in Nephrology, GRUNE AND STRATTON, NEW YORK, NY., US, US , (20150301), vol. 35, no. 2, doi:10.1016/j.semnephrol.2015.02.002, ISSN 0270-9295, pages 125 - 136, XP093009053 | |
| OPPOSITION | - Weber, M.A. ; Black, H. ; Bakris, G. ; Krum, H. ; Linas, S. ; Weiss, R. ; Linseman, J.V. ; Wiens, B.L. ; Warren, M.S. ; Lindholm, L.H., "A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20091024), vol. 374, no. 9699, doi:10.1016/S0140-6736(09)61500-2, pages 1423 - 1431, XP026705648 | |
| OPPOSITION | - Schlaich Markus P, Bellet Marc, Et Al., "Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial", The Lancet, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20221201), vol. 400, no. 10367, doi:10.1016/S0140-6736(22)02034-7, pages 1927 - 1937, XP093052465 | |
| OPPOSITION | - "32 Therapy of Hypertension", Laurence Brunton, Keith Parker, Donald Blumenthal, lain Buxton, Goodman & Gilman’s Manual of Pharmacology and Therapeutics, United States of America, McGraw-Hill , (20080101), pages 544 - 560, doi:10.1036/0071443436, ISBN 0-07-144343-6, XP009561948 | |
| OPPOSITION | - Laurence Brunton, Keith Parker, Donald Blumenthal, lain Buxton, "33 PHARMACOTHERAPY OF CONGESTIVE HEART FAILURE", Laurence Brunton, Keith Parker, Donald Blumenthal, lain Buxton, Laurence Brunton, Keith Parker, Donald Blumenthal, lain Buxton, Goodman & Gilman’s Manual of Pharmacology and Therapeutics, United States of America, McGraw-Hill , (20080101), pages 561 - 577, doi:10.1036/0071443436, ISBN 0-07-144343-6, XP009561947 | |
| OPPOSITION | - Sica Domenic A., "The Kidney and Hypertension: Causes and Treatment", The Journal of Clinical Hypertension, (20080822), vol. 10, no. 7, doi:10.1111/j.1751-7176.2008.08189.x, pages 541 - 548, XP093282273 | |
| OPPOSITION | - Mona Selej, Alain J. Romero, Richard N. Channick, Martine Clozel, "Development of macitentan for the treatment of pulmonary arterial hypertension : Macitentan for the treatment of pulmonary arterial hypertension", Annals of the New York Academy of Sciences, New York Academy of Sciences., US, US , (20151101), vol. 1358, no. 1, doi:10.1111/nyas.12856, ISSN 0077-8923, pages 68 - 81, XP055703561 | |
| OPPOSITION | - Trensz Frederic, Bortolamiol Céline, Kramberg Markus, Wanner Daniel, Hadana Hakim, Rey Markus, Strasser Daniel S., Delahaye Stéphane, Hess Patrick, Vezzali Enrico, Mentzel Ulrich, Ménard Joël, Clozel Martine, Iglarz Marc, "Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension", The journal of pharmacology and experimental therapeutics, Elsevier Inc, United States, United States, (20190301), vol. 368, no. 3, doi:10.1124/jpet.118.253864, ISSN 0022-3565, pages 462 - 473, XP093282269 | |
| OPPOSITION | - Chang Yoon-Kyung, Choi Hyunsu, Jeong Jin Young, Na Ki-Ryang, Lee Kang Wook, Choi Dae Eun, "Co-inhibition of Angiotensin II Receptor and Endothelin-1 Attenuates Renal Injury in Unilateral Ureteral Obstructed Mice", KIDNEY AND BLOOD PRESSURE RESEARCH, BASEL, CH, CH , (20160101), vol. 41, no. 4, doi:10.1159/000443446, ISSN 1420-4096, pages 450 - 459, XP093282272 | |
| OPPOSITION | - Bo Yang, Chen Yun-Dai, Li Tian-De, Feng Quan-Zhou, "Endothelin-1 receptor blockade induces upregulation of renin-angiotensin-aldosterone system expression in terms of blood pressure regulation", JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, Sage Publications Ltd., GB, GB , (20100601), vol. 11, no. 2, doi:10.1177/1470320309358108, ISSN 1470-3203, pages 119 - 123, XP093282270 | |
| OPPOSITION | - S Pabani, S A Mousa, "Current and future treatment of pulmonary hypertension", Drugs of today (Barcelona, Spain : 1998), United States, United States , doi:10.1358/dot.2012.48.2.1703662, (20120201), pages 133 - 147, Drugs of today (Barcelona, Spain : 1998), URL: http://www.ncbi.nlm.nih.gov/pubmed/22384453, XP055127148 | |
| SEARCH | - Brunton Laurence ET AL, "Goodman and Gilman's Manual of Pharmacology and Therapeutics, section of chapters 32 and 33", Goodman and Gilman's Manual of Pharmacology and Therapeutics, section of chapters 32 and 33, McGraw Hill Medical, (20081231), XP055915454 [Y] 1-16 * page 554, paragraph 4 - paragraph 5 * * paragraphs 4 and 7; page 555 * * page 560, paragraph 5 * * bridging paragraph; page 566 - page 567 * * page 567, paragraph 5 * | - |
| SEARCH | - S Pabani ET AL, "Current and future treatment of pulmonary hypertension", Drugs of today (Barcelona, Spain : 1998), United States, doi:10.1358/dot.2012.48.2.1703662, (20120201), pages 133 - 147, URL: http://www.ncbi.nlm.nih.gov/pubmed/22384453, XP055127148 [Y] 1-16 * page 140 * * 1st paragraph, Introduction; page 134 * | |
